Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Research in Sciences

Saccharomyces cerevisiae as A Fusion Inhibitor of Sars-Cov-2

Submission: February 05, 2021;Published: March 02, 2021

Resume

SARS-CoV-2 interacts with prokaryotic translation elongation factors (eEFs), predominantly eEF1A. This connection occurs at the intracellular level, when the virus is linked to ribosomes, necessary for viral replication. The fungus Saccharomyces cerevisiae has an abundance of eEF1A protein, and its dietary supplementation can increase serum protein levels, which, by binding to viruses circulating in the blood, prevent the entry of these cells, thus preventing viral replication; in addition, exposes the virus to the body’s humoral immune system. Supplementation through the diet of the fungus Saccharomyces cerevisiae would work as a fusion inhibitor drug, a mechanism of action of some antivirals.

Get access to the full text of this article


About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com